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Abstract
Acute chest syndrome (ACS) is defined as fever, respiratory symptoms and a new pulmonary
infiltrate in an individual with sickle cell disease (SCD). Nearly half of ACS episodes occur in
SCD patients already hospitalized, potentially permitting pre-emptive therapy in high-risk
patients. Simple transfusion of red blood cells may abort ACS if given to patients hospitalized for
pain who develop fever and elevated levels of secretory phospholipase A2 (sPLA2). In a
feasibility study (PROACTIVE; ClinicalTrials.gov NCT00951808), patients hospitalized for pain
who developed fever and elevated sPLA2 were eligible for randomization to transfusion or
observation; all others were enrolled in an observational arm. Of 237 enrolled, only 10 were
randomized; one of the four to receive transfusion had delayed treatment. Of 233 subjects
receiving standard care, 22 developed ACS. A threshold level of sPLA2 ≥ 48 ng/ml gave optimal
sensitivity (73%), specificity (71%) and accuracy (71%), but a positive predictive value of only
24%. The predictive value of sPLA2 was improved in adults and patients with chest or back pain,
lower haemoglobin concentration and higher white blood cell counts; and those receiving less than
two-thirds maintenance fluids. The hurdles identified in PROACTIVE should facilitate design of a
larger, definitive, phase 3 randomized controlled trial.
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Introduction
Acute chest syndrome (ACS), characterized by fever, respiratory symptoms and a new
pulmonary infiltrate, is responsible for much of the morbidity of sickle cell disease (SCD), is
the second most common cause of hospitalization, and is the leading cause of death (Platt, et
al 1994, Sprinkle, et al 1986, Vichinsky 1991). A majority of patients will experience at
least one episode of ACS, and repeated episodes can result in progressive lung disease
(Powars, et al 1988, Weil, et al 1993). Fifty percent of patients who develop ACS are
initially admitted with other diagnoses, such as acute pain episodes and only subsequently
develop ACS (Vichinsky, et al 2000). Transfusion is widely used to treat ACS and leads to
rapid clinical improvement, especially when used early after onset (Mallouh and Asha 1988)
The aetiology of ACS is multifactorial, but the various causes initiate a similar cascade of
events that can rapidly cause serious lung injury (Castro, et al 1994, Johnson and Verdegem
1988, Kolquist, et al 1996, Vichinsky, et al 2000, Vichinsky, et al 1997, Vichinsky, et al
1994). The exact pathophysiology of ACS is not known but several studies have implicated
secretory phospholipase A2 (sPLA2) in its pathogenesis (Ballas, et al 2006, Kuypers and
Styles 2004, Kuypers, et al 1999, Naprawa, et al 2005, Styles, et al 2000, Styles, et al 2007,
Styles, et al 1996). Type IIa sPLA2 is a calcium-dependent protein that cleaves
phospholipids to generate non-esterified fatty acids and lysophospholipids. sPLA2 is
secreted by many cells within the body and is induced by inflammatory signals, such as
tumour necrosis factor (TNF) and interleukin-1 (IL1) (Pfeilschifter, et al 1989). By
generating important intermediates, such as arachidonic acid or lysoplatelet activating
factor, sPLA2 appears to play an important role as a mediator between the proximal and
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distal effectors of inflammation (Henderson 1987, Lewis, et al 1990). Elevations of sPLA2
have been reported in many disease states in which inflammation is prominent, including
sepsis and acute respiratory distress syndrome (ARDS) (Anderson, et al 1994, Baur, et al
1989, Green, et al 1991, Koike, et al 2000, Nevalainen 1993, Smith, et al 1992).
Previous studies of sPLA2 in SCD have shown that sPLA2 is elevated in ACS; sPLA2
levels correlate with clinical severity and levels often rise in the 24 to 48 h before ACS is
diagnosed clinically. In preliminary studies, a threshold of 100ng/ml best predicted
impending ACS (Ballas, et al 2006, Styles, et al 2000, Styles, et al 2007, Styles, et al 1996).
A subsequent pilot intervention trial provided evidence that ACS could be prevented by
transfusion, when using sPLA2 levels and fever to predict those at risk for ACS (Styles, et al
2007). The Sickle Cell Disease Clinical Research Network (SCDCRN) initiated the
feasibility study “Preventing Acute Chest Syndrome with Transfusion Trial” (PROACTIVE)
to better establish the accuracy of sPLA2 as a predictor of ACS and to confirm results of
previous studies. This report documents the results of this study.
Methods
PROACTIVE was a feasibility study to determine if elevation of serum levels of sPLA2
could be used along with transfusion to prevent ACS. This study had two primary
objectives. The first was to assess the feasibility of recruiting a sufficient number of eligible
subjects to a randomized interventional trial of transfusion vs. standard care such that: a)
consent to the trial and randomization occurred within 8 h of eligibility determination; b)
initiation of the experimental transfusion occurred within 14 h of eligibility determination;
and c) 40 subjects could be randomized in 12 months. The second objective was to optimize
the utility of serum sPLA2 levels in predicting imminent ACS. Twenty-six centres were
contracted to enroll patients to PROACTIVE. All sites obtained Human Subjects approval
with local Institutional Review Boards. All patients consented to participation in the study
prior to enrollment.
Study design
This feasibility study for PROACTIVE included two design components: Component 1: The
PROACTIVE randomized controlled interventional trial protocol with a target enrollment of
40 subjects (20 in each treatment group); and Component 2: An observational cohort
consisting of an estimated 300 subjects ineligible for the interventional trial, either because
they failed to meet randomization criteria or developed ACS prior to randomization. The
trial duration was to be 13 months, with an expected recruitment of 40 randomized
participants in 12 months.
Study Flow
All SCD patients (Hb SS, SC or S-β0 or S-β+ thalassaemia) aged ≥ 2 years who were
admitted to the hospital with acute pain and no evidence of ACS were asked to participate in
the screening/observational protocol. Subjects were excluded for medical conditions for the
which the physician felt a transfusion was likely, transfusions in the last 60 days, or
conditions making transfusion unacceptable or difficult (such as multiple alloantibodies). A
maximum of three daily SPLA2 levels were determined and comprehensive clinical and
laboratory data were collected. Those with fever on admission or who developed a fever
during the screening phase received a clinically indicated chest X-ray (CXR); if positive for
infiltrate they remained in the observational protocol if other randomization criteria had not
been met. Subjects who had three daily sPLA2 levels < 100 ng/ml also remained in the
observational protocol and a CXR was required at 72 h or at the time of discharge if
discharge occurred prior to 72 h.
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Subjects who had a positive screening sPLA2 (>100 ng/ml) had a study-mandated CXR as
soon as the sPLA2 elevation was detected. To be eligible for randomization, subjects
required all of the following at the time of randomization:
1. sPLA2 level > 100 ng/ml within the same 24-h window as fever (temperature>
38.0° C) and a CXR that was negative for new pulmonary infiltrate. If a negative
CXR was not done within the 12 h preceding randomization, a repeat CXR was
required to confirm eligibility.
2. Hb <100 g/dl
3. Signed consent/assent for participation in the randomized interventional trial.
ACS was defined as having a new infiltrate on a CXR as read by the local site. Reported
positive CXR results were later compared with study forms to confirm the diagnosis of
ACS. If a CXR was reported positive but a diagnosis of ACS was not made, these CXR
reports were retrieved from the sites and blindly and independently reviewed by Drs. Styles
and Miller to determine whether or not ACS was present.
Transfusion arm subjects received a single transfusion of 7–13 ml/kg packed red blood cells
(PRBC) within 14 h of eligibility determination. In addition to ABO/Rh, PRBC transfusions
were to be, at a minimum, phenotypically matched for the E, C, and K1 antigens. Subjects
not randomized to transfusion and those in the observational cohort received standard care.
Quantitative sPLA2 protein measurements
SPLA2 measurements were determined every 24 h. The measurements were performed by
enzyme-linked immunosorbent assay (ELISA; Cayman Chemicals, Ann Arbor, MI, USA)
using serum in the following manner: Strip wells were pre-coated with a mouse capture
antibody and blocked with a proprietary formulation of proteins, both obtained from
Cayman Chemicals. An eight-point standard curve of sPLA2 (13 ng/ml to 600 ng/ml) was
supplied. High, mid, and low quality control (QC) standards were supplied at 200, 100, and
50 ng/ml, respectively
The linear range for quantitation in the assay was claimed by the manufacturer to be 25 –
400 ng/mL. The assay acceptance criteria required that all three QC standards have accuracy
between 80% and 120%, with special provisions for accepting values between 25 – 100 or
100 – 400 if only the high QC standard or the low QC standard failed, respectively. The
assay was validated in the manufacturer’s laboratory to have accuracy and precision (%CV)
within 15%.
Statistical Analyses
The analysis subset included subjects that had no transfusions and at least one sPLA2 value
during the study prior to either discharge or ACS diagnosis. The primary predictor variable
was the maximum sPLA2 value prior to ACS diagnosis or discharge.
In a preliminary analysis, potential threshold levels of sPLA2 were evaluated with regard to
their impact on the sensitivity (true positive rate; TPR), false positive rate (FPR; 1 –
specificity), accuracy (ACC; number of correct classifications), and positive predictive value
(PPV) of developing ACS. The area under the curve (AUC) for the Receiver Operating
Characteristic (ROC) was examined to assess whether maximum sPLA2 had an overall
adequate predictive ability across the range of candidate thresholds. The optimal threshold
level for sPLA2 was defined to be that which provided the largest difference between the
TPR and the FPR. The analysis was repeated for paediatric and adult subgroups, as well as
for subjects with and without fever.
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The data were further analysed to determine if the threshold levels of other clinical variables
would enhance the predictive ability for ACS diagnosis. Both continuous and discrete
variables were analysed, including fever, respiratory and heart rate, reported sites of pain,
breath signs (rales, decreased breath sounds, shortness of breath, cough, or wheezing),
oxygen saturation, whether incentive spirometry was ordered, IV rate, specific drugs taken
(including hydroxycarbamide), number of previous ACS hospitalizations reported, and
laboratory findings, including red and white blood cell counts, reticulocytes, platelets, and
haemoglobin. For each of these variables, both baseline and maximum/minimum or any/
none during the study period was considered, and three types of binary classification
analyses were conducted: Univariate analyses determined the optimal threshold level for
each independent variable in predicting ACS. Composite analyses determined the optimal
threshold levels for sPLA2 in combination with one or two other variables in predicting
ACS. Two-stage screening analyses determined the optimal threshold levels for predicting
ACS when the data was first partitioned into two subgroups by a threshold level for a (non-
sPLA2) clinical sign or symptom, then partitioned by the optimal threshold level for sPLA2
within each data subgroup. The goal, determined a priori, was to identify predictive
combinations (possibly within subgroups) that yielded a PPV ≥ 40%, while still maintaining
a TPR ≥ 70% and FPR ≤ 20%.
Finally, classification trees (Breiman 1984) were constructed to identify subgroups of
subjects that had high prevalence of ACS. Using this methodology, the study population was
recursively partitioned into two groups based upon a splitting rule that effectively
maximized the prevalence for ACS within one of the subgroups (without regard for the
sensitivity and specificity). To enhance the validity of the trees, the candidate variables
considered for splitting were restricted to those pre-determined to have a high predictive
ability of ACS, based upon a conditional forest analysis (Strobl, et al 2008).
All analyses were done for the combined adult/paediatric population, as well as separately
for adults (age ≥ 18 years) and children (age < 18 years).
Results
During the study period, there were 2302 SCD admissions for pain at all participating
institutions. Of these, 420 patients were recognized as eligible for enrollment and 237 were
enrolled (Fig 1). The reasons patients were recognized as eligible but excluded from
enrollment are summarized in Table I. Of the 233 subjects receiving standard care, 30 were
excluded from the analysis subset; seven had insufficient sPLA2 data and 23 received
clinically indicated transfusions prior to an ACS diagnosis or discharge. Descriptive
characteristics for the remaining 203 subjects are shown in Table II. Children made up a
greater percentage of enrolled subjects. Of the 23 subjects initially reported to have a new
infiltrate on CXR, six lacked a corresponding diagnosis of ACS on the daily study form; on
review, five had ACS and one did not. Although adults had lower overall sPLA2 levels, they
had similar rates of developing ACS (11.5% vs. 10.3%). Management and clinical course of
enrolled subjects are described elsewhere (Miller, et al 2012); no deaths occurred during the
trial.
Only 10 subjects met the criteria for randomization into the interventional trial; four were
randomized to the transfusion arm and six to standard care. All 10 subjects were randomized
within 8 h of eligibility (mean: 3.4 h, range: 0.4–7.5 h). Three of four subjects randomized to
transfusion were transfused within the mandated six hours from randomization (2.9, 4.3, and
5.9 hours) and within 14 hours of eligibility (3.3, 7.9, and 13.3 hours). One subject was
transfused 23.9 h after eligibility and 20.8 h after randomization due to unavailability of an
inpatient hospital bed required for a study-indicated transfusion. None of the four subjects
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randomized to the transfusion arm developed ACS, while two of the six subjects (33%)
randomized to standard care developed ACS.
Threshold of sPLA2 prior to ACS diagnosis
The analysis subset included 203 subjects, of which 22 developed ACS during the study and
181 did not. A cross-tabulation of ACS status with the predetermined sPLA2 threshold of
100 ng/ml showed that 13 of 161 patients below this threshold developed ACS (8%) and 9
of 42 at or above this threshold developed ACS (21%); this threshold corresponded to a
sensitivity of 41%, specificity of 82%, accuracy of 77%, and PPV of 21%.
The analyses of all potential threshold levels in the combined adult and paediatric study
population (Fig 2) suggested that sPLA2 ≥ 48 ng/ml provided the optimal trade-off between
sensitivity (73%), specificity (71%), and accuracy (71%); however, this threshold yielded a
PPV of only 24%. The ROC curve demonstrated adequate overall predictive ability of
sPLA2 (AUC=0.72). The presence of fever within 24 h of the maximum sPLA2 did not
improve the predictive ability (data not shown). Analysis of the paediatric (n=107) and adult
(n=96) subgroups demonstrated that sPLA2 was an adequate predictor of ACS in both
subgroups (AUC=0.72 for both). The threshold of sPLA2 ≥ 48 ng/ml was also optimal in
both age groups; however, in adults, it yielded a higher PPV of 37% and lower sensitivity of
64%, whereas in children it yielded a higher sensitivity of 82% and lower PPV of 18%.
In adults, the univariate analyses identified that haemoglobin concentration ≤ 70 g/l yielded
a PPV of 40% (TPR=73%, FPR=15%); 20 adults (21%) fell below that threshold. No other
univariate potential predictors of ACS achieved PPV > 40% while maintaining adequate
sensitivity and specificity for either the combined population or the paediatric subgroup.
The composite analyses identified that having both sPLA2 ≥ 48 ng/ml and baseline white
blood cell count (WBC) ≥ 10.4 × 109/l yielded a PPV of 38% (TPR=73%, FPR=15%) in the
combined adult/paediatric population. In the adult subgroup, no composite predictors
achieved adequate (≥ 70%) sensitivity. In children, the combination of sPLA2 ≥ 31 ng/ml
and baseline haemoglobin ≤ 74 g/l yielded a PPV of 44% (TPR=73%, FPR=11%). A three-
way composite analysis of these important predictors identified that having sPLA2 ≥ 31 ng/
ml combined with baseline WBC ≥ 10.4 × 109/l, and baseline haemoglobin ≤ 93 g/l yielded
a PPV of 43% (TPR=73%, FPR=15%) in the combined adult/paediatric population; 37
subjects met this criteria (16 developed ACS). The two-stage screening analyses identified
that sPLA2 ≥ 77 ng/ml yielded a PPV of 42% (TPR=73%, FPR=14%) among all subjects
who reported back pain at baseline, and sPLA2 ≥ 55 ng/ml yielded a PPV of 41%
(TPR=75%, FPR=19%) among all subjects who reported chest pain on any day during the
study.
The classification tree analysis (Fig 3) confirmed the other findings. In the combined adult/
paediatric population, the first split of minimum haemoglobin < 71 g/l at any time during
hospital stay before ACS or discharge yielded 40 subjects that had 35% prevalence of ACS.
The subsequent split of baseline intravenous infusion rate ≥ 68% of maintenance yielded a
group of 28 subjects that had 50% prevalence of ACS. There were no subjects with baseline
IV rate < 68% and minimum haemoglobin < 71 g/l that developed ACS; and the subsequent
split on the left side of the tree yielded 7 subjects with minimum haemoglobin > 70 g/l and
baseline WBC ≥ 20.1 × 109/l of which 3 (43%) developed ACS. In adults, the first split was
identical to that of the combined adult/paediatric population: 20 adults had a minimum
haemoglobin ≤ 70 g/l, of which eight (40%) developed ACS. In children, the first split of
minimum haemoglobin < 75 g/l yielded a group of 27 subjects that had a 30% prevalence of
ACS, and the subsequent split yielded 8 children with baseline chest pain and minimum
haemoglobin < 75 g/l of which 6 (75%) subsequently developed ACS.
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Regardless of aetiology, the course of ACS is often severe, with multiple lobe involvement,
hypoxia and rapid progression despite aggressive intervention (Castro, et al 1994,
Vichinsky, et al 2000, Vichinsky, et al 1997). ACS is frequently associated with vaso-
occlusive pain episodes and these ACS events are particularly severe (Vichinsky, et al
2000). Even one episode of ACS leads to a shortened life expectancy (Platt, et al 1994).
Given the morbidity and consequences of ACS, there is considerable interest in identifying
efficacious treatments and, ultimately, in preventing its occurrence altogether.
Blood transfusion was chosen as the best potential therapy to prevent ACS based on its
demonstrated therapeutic effects. Transfusion early in the course of ACS has been found to
hasten resolution (Mallouh and Asha 1988), has beneficial effects on oxygenation (Emre, et
al 1995, Vichinsky, et al 2000), and appears to reduce occurrence if given
preventively(Hankins, et al 2005, Miller, et al 2001). It has been speculated that transfusion
may impact by down-regulating vascular cellular adhesion molecule 1 (Liem, et al 2004,
Sakhalkar, et al 2004, Stuart and Setty 1999) and/or perhaps by providing Duffy antigen,
which is largely lacking in sickle cell populations and, at least in vitro, modifies the effects
of cytokine release, most notably IL-8 (Abboud, et al 2000, Afenyi-Annan, et al 2008,
Hadley and Peiper 1997). It is not known whether transfusion has any direct effect upon the
production, activity or metabolism of sPLA2. A pilot study utilizing sPLA2 as a predictor
for ACS demonstrated that transfusion prior to clinically apparent ACS reduced its
occurrence (Styles, et al 2007) and, based on this, the SCDCRN designed the PROACTIVE
trial.
Given that large controlled trials have historically been difficult to undertake in SCD,
especially in the inpatient setting, PROACTIVE was redesigned as a feasibility trial. It is of
some concern that our goal of randomizing 40 subjects in 12 months was not achieved, even
with the participation of 26 centres. Of 2302 patients hospitalized for pain, less than 10%
were enrolled for possible randomization. Difficulties with staffing at sites, limited or non-
availability of the sPLA2 assay on weekends, and inability to get consent under the rigorous
time constraints of the study were common reasons for failure to enroll patients. These are
important factors that will have to be addressed prior to proceeding with larger trials.
The often subtle presentation and subsequent rapidly progressive course of ACS and
uncertainty regarding the time needed for potential therapeutic impact of transfusion
mandated a small window between ascertainment of eligibility (including a lack of ACS)
and administration of treatment; that transfusion therapy cannot be safely blinded
compounds these potential issues. The window of 14 h between eligibility and initiation of
treatment was a compromise between this need for expeditious therapy and anticipated
impediments to prompt randomization and preparation for transfusion. As one of four
subjects randomized to transfusion experienced inordinate delay of therapy, our limited data
suggest an eligibility-to-treatment interval similar to that chosen for PROACTIVE may be
difficult to achieve; additional potential subjects may have been excluded from enrollment
because timely transfusion at the site clearly could not have been accomplished. For future
studies, a longer interval between randomization and transfusion may be necessary;
however, the maximum duration in the PROACTIVE of 26 hours between the eligibility-
establishing negative chest radiograph and initiation of transfusion therapy is already
generous given the (sometimes) rapid progression of ACS. The small numbers of patients
enrolled in PROACTIVE precluded any assessment of the effectiveness of transfusion.
Data from the patients enrolled in the observational component of the trial allowed us to
evaluate the pre-established sPLA2 threshold of 100 ng/mL. This threshold showed good
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specificity, but inadequate sensitivity. The paucity of ACS events in this study population
contributed to the low PPV for all thresholds of sPLA2 considered. From a clinical
standpoint, a higher PPV would reduce the number of patients “unnecessarily” transfused
due to a spurious high-risk screening level; we chose a PPV of 40% as a reasonable clinical
threshold. Of the several other clinical and laboratory variables examined, only low
haemoglobin in adults (≤ 70 g/l) performed better than sPLA2 in prediction of ACS in our
overall study population. A threshold of 48 ng/ml provided better sensitivity while
preserving adequate accuracy and minimal reduction in specificity. The sPLA2 assay had
similar overall predictive ability in adults versus children as well as the same optimal
threshold in the two age groups, but the accuracy and positive predictive value was better in
adults and the sensitivity was better in children. In general, children achieved higher sPLA2
values than adults. It is not known why the assay was more predictive in adults; adults do
tend to have more severe ACS and a higher mortality rate (Vichinsky 1997, Vichinsky, et al
2000), and perhaps a difference in aetiology of ACS between adults and children could
impact sPLA2 values.
The pre-established threshold of 100 ng/ml for sPLA2 was effective in a small pilot study
(Styles, et al 2000) and validated in a larger, multi-institutional cohort (Ballas, et al 2006).
sPLA2 assays used in previous clinical studies have included both activity of sPLA2 and
protein concentration of sPLA2. Correlation between sPLA2 concentration and activity has
been excellent so this does not appear to explain the differences in results (Styles, et al
1996). The ELISA-based assay used in this study to measure sPLA2 protein was developed
separately from that used in previous trials. Given the disparity between the ELISA results
from this study and that of previous reports, it would be wise to initiate a comparison of both
ELISA assays with known samples to determine if there are differences between the two
assays themselves or if the differences are the result of operator variation. In addition, due to
the recognition of sPLA2 as a potential risk factor for coronary artery disease (Koenig, et al
2009), several commercial assay kits have recently become available. It will be particularly
important for future studies to define an optimal threshold for whatever methodology is
utilized.
Fever had previously been identified as a clinical indicator that improved the accuracy of the
sPLA2 assay by eliminating many false positives. However, when the optimal threshold
analysis was repeated for patients with and without fever, the presence of fever did not
improve accuracy of the sPLA2 assay in predicting ACS. The univariate analyses identified
only that in adults a low haemoglobin concentration (at or below 70 g/l) was helpful in
predicting ACS independent of other variables. The composite analysis identified the
combination of low haemoglobin level and an elevated sPLA2 as being predictive in
children; no composite variables were identified to predict ACS in the adult group. A two-
stage screening analysis revealed that in subjects with back pain or chest pain, it was
possible to achieve adequate predictive ability (PPV ≥ 40%) using sPLA2 as a diagnostic
criterion; chest pain may have been reflective of impending ACS. In addition, both chest and
back pain may have led to splinting, which may contribute to the development of ACS
(Bellet, et al 1995, Gelfand, et al 1993, Needleman, et al 2002, Rucknagel 2001). In the
overall study population, the combination of elevated WBC and elevated sPLA2 was
predictive; a better PPV (43%) was obtained when low haemoglobin concentration was
added to the criteria. Finally, the classification tree analysis confirmed the findings in the
other analyses by identifying that low haemoglobin and elevated WBC led to a higher rate of
ACS in patients; it is of interest that a previous study of occurrence of ACS in hospitalized
children with sickle cell disease identified high WBC and low haemoglobin levels were
associated with nosocomial ACS (Buchanan, et al 2005).
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The classification tree analysis also revealed that IV fluid infusion rates above 2/3
maintenance were associated with a higher rate of ACS. In light of the clinical and
radiological findings consistent with pulmonary oedema in many SCD patients with ACS,
this finding suggests that hydration should be used judiciously in patients admitted with pain
(Ardiles and Dark 2007, Girard 1979, Haynes and Allison 1986). Many investigators in
PROACTIVE were restrictive in fluid administration during the study(Miller, et al 2012);
further restriction of fluid provision among clinical centres might further reduce the
incidence of nosocomial ACS. The impact of fluid administration on the course of a pain
episode is unknown.
In conclusion, the PROACTIVE study suffered from many of the difficulties seen in other
studies in SCD and other rare diseases, including challenges in meeting enrollment goals.
Adjustments in availability of study personnel may be required to optimize recruitment, and
focusing on those patients at highest risk, i.e. with lower haemoglobin, higher WBC count
and chest or back pain, might reduce projected numbers of randomized patients needed to
assess treatment efficacy. SPLA2 levels accurately predicted ACS but further clarification of
optimal sPLA2 methodology and thresholds is needed to assess definitively its potential
clinical role. ACS continues to be an important problem in SCD, and efforts to improve
treatment and prevention must continue. The hurdles identified in PROACTIVE should
facilitate design of a larger, definitive, Phase 3 randomized controlled trial to determine
whether transfusion can indeed prevent ACS in selected patients hospitalized for pain.
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Fig 1. Disposition of Patients in Study
Tx, transfusion, SC, standard care; sPLA2, secretory phospholipase A2; ACS, acute chest
syndrome.
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Fig 2. Classification Rates for predicting ACS in adults and children
For each threshold level of sPLA2, true positives (TP), true negatives (TN), false positives
(FP), and false negatives (FN) were tabulated and used to compute the following rates:
accuracy (ACC = (TP+TN)/(TP+TN+FP+FN)), sensitivity (TPR = TP/(TP+FN)), specificity
(1 – FPR = TN/(FP+TN)), positive predictive value (PPV = TP/(TP+FP)), and negative
predictive value (NPV = TN/(FN+TN)).
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Fig 3. Classification trees
Within each age group, data was recursively partitioned into two groups based upon a
splitting rule that effectively optimized the prevalence within one of the subgroups. The
candidate splits included all possible threshold levels for clinical predictors that were
determined to have high predictive ability in this data. The number of subjects and the rate
of ACS are reported within each node.
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Table I
Reasons screened subjects were excluded from enrollment
Number Screened 420
• Did not meet inclusion criteria 42
 ○ Acute chest syndrome present at screening 31
 ○ Lack of acute pain diagnosis 10
 ○ Prior Enrollment in PROACTIVE Feasiblity Study 1
• Met at least one exclusion criterion 120
 ○ RBC transfusion within last 60 days 46
 ○ History of alloimmunization 20
 ○ Transfusion-dependent coexisting medical condition 17
 ○ Diagnosis of pulmonary infiltrate 7
 ○ Various combinations of above 22
 ○ Pregnant 3
 ○ Objection to transfusion 3
 ○ Treated with systemic steroids in previous week 2
• Eligible Subjects 258
 ○ No signed consent 21
 ○ Enrolled 237
PROACTIVE, Preventing Acute Chest Syndrome with Transfusion Trial; RBC, red blood cell
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Table II
Baseline demographic characteristics
N (%) Overall (N=203)
Age group
Paediatric (N=107) Adult (N=96)
Gender (male) 102 (50%) 58 (54%) 44 (46%)
Race (black) 198 (98%) 103 (96%) 95 (99%)
Range of maximum sPLA2 value
 >0 – 25 106 (52%) 43 (40%) 63 (66%)
 >25 – 50 34 (17%) 18 (17%) 16 (17%)
 >50 – 100 22 (11%) 16 (15%) 6 (6%)
 >100 – 200 13 (6%) 9 (8%) 4 (4%)
 >200 – 800 28 (14%) 21 (20%) 7 (7%)
Acute Chest Syndrome 22 (11%) 11 (10%) 11 (11%)
sPLA2, secretory phospholipase A2
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